<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937530</url>
  </required_header>
  <id_info>
    <org_study_id>RT001-013</org_study_id>
    <nct_id>NCT04937530</nct_id>
  </id_info>
  <brief_title>RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY</brief_title>
  <official_title>A Randomized, Double-blind, Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Progressive Supranuclear Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retrotope, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retrotope, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled trial of RT001 in patients with PSP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled trial of RT001 in patients with PSP to assess the&#xD;
      efficacy, safety and tolerability of RT001. Subjects will be randomized to RT001 or placebo&#xD;
      and will receive study drug for 48 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the PSPRS-28 at 48 weeks for the RT001 treated group vs placebo-treated group</measure>
    <time_frame>48 weeks</time_frame>
    <description>The PSPRS-28 is a clinician-rated instrument to assess disability and severity of PSP. The PSPRS-28 evaluates 28 items in six categories: daily activities (by history), behavior, bulbar, ocular motor, limb motor and gait/midline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>RT001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT001 960 mg capsule. 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive comparator capsule 960 mg (safflower oil). 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RT001</intervention_name>
    <description>RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 11 months</description>
    <arm_group_label>RT001</arm_group_label>
    <other_name>di-deuterated linoleic acid ester</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>safflower oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign the informed consent form prior to entry into the study&#xD;
&#xD;
          2. Male or female subject with age 40 years to 80 years at the time of signed consent&#xD;
&#xD;
          3. Meets the MDS-PSP study group criteria for possible or probable progressive&#xD;
             supranuclear palsy with Richardson syndrome (postural instability and falls with&#xD;
             vertical ocular motor dysfunction)&#xD;
&#xD;
          4. Presence of PSP symptoms for less than 4 years&#xD;
&#xD;
          5. Score of &lt;40 on the PSPRS-28&#xD;
&#xD;
          6. Ambulatory patients (with or without assistive device - no handheld help) and capable&#xD;
             of performing study assessments/evaluations&#xD;
&#xD;
          7. Subject has an identified, reliable, study partner (e.g., caregiver, family member,&#xD;
             social worker, or friend) who can assist in assuring that the subject is able to&#xD;
             travel to the required visits.&#xD;
&#xD;
          8. Willing to provide the necessary blood samples&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received treatment with other experimental therapies within the last 30 days prior to&#xD;
             the first dose. The last dose of the prior experimental agent must have occurred more&#xD;
             than 5 half-lives prior to enrollment in the current trial.&#xD;
&#xD;
          2. Previously received treatment with RT001&#xD;
&#xD;
          3. Refusal to discontinue fish oils or other oil-based supplements for the duration of&#xD;
             the study (Screening/Baseline till last study procedure completed)&#xD;
&#xD;
          4. Mini mental state examination (MMSE) score less than 20 at screening&#xD;
&#xD;
          5. Subject resides at a skilled nursing or dementia care facility, or admission to such a&#xD;
             facility is planned during the study period&#xD;
&#xD;
          6. Evidence of any clinically significant neurological disorder other than PSP in&#xD;
             particular CBS&#xD;
&#xD;
          7. Evidence of a clear and robust benefit from levodopa at the time of screening.&#xD;
             Participants are permitted to take levodopa and other Parkinson's medications if the&#xD;
             dose had been stable for 60 days prior to screening&#xD;
&#xD;
          8. The subject has a history of or currently has schizophrenia, schizoaffective disorder&#xD;
             or bipolar disorder according to DSM-V or ICD-10 criteria&#xD;
&#xD;
          9. Subject has had a significant illness or infection requiring medical intervention in&#xD;
             the past 30 days&#xD;
&#xD;
         10. Subject has evidence of any disease or condition (based on either history, physical or&#xD;
             laboratory values) that might interfere with the conduct of the study&#xD;
&#xD;
         11. Is currently receiving active deep brain stimulation (DBS) that cannot be turned off&#xD;
&#xD;
         12. Any condition with a life expectancy of less than 2 years&#xD;
&#xD;
         13. Female who is breastfeeding or has a positive pregnancy test&#xD;
&#xD;
         14. Male participant or female participant of childbearing potential, who is sexually&#xD;
             active and unwilling/unable to use a highly effective birth control method throughout&#xD;
             the study&#xD;
&#xD;
         15. Unwilling or unable to comply with the requirements of this protocol, including the&#xD;
             presence of any condition (physical, mental, or social) that is likely to affect the&#xD;
             subject's ability to return for visits as scheduled&#xD;
&#xD;
         16. History, within the last 2 years, of alcohol abuse or physical opioid dependence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Lorenzl, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Maximilians - University of Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark G. Midei, MD</last_name>
    <phone>(650) 437-0700</phone>
    <email>mark@retrotope.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Agaharied Teaching Hospital, University of Munich</name>
      <address>
        <city>Munich</city>
        <state>MD</state>
        <zip>21111</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark G. Midei, MD</last_name>
      <email>mark@retrotope.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

